Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calling for Diversity: Improving Transfusion Safety Through High-Throughput Blood Group Microarray Genotyping.

Genomics, proteomics & bioinformatics·2026
Same author

Single-cell profiling reveals CCL5Hi GZMAHi effector memory CD8 T cell association to oligoarticular JIA.

Rheumatology (Oxford, England)·2026
Same author

A Bifactor Measure of Societal Stigma Toward Eating Disorders and Obesity: Scale Development and Validation.

International journal of environmental research and public health·2026
Same author

Publisher Correction: Interpretable inflammation landscape of circulating immune cells.

Nature medicine·2026
Same author

Interpretable inflammation landscape of circulating immune cells.

Nature medicine·2026
Same author

Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jun 13, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Rheumatoid arthritis pharmacogenomics.

Sara Marsal1, Antonio Julià

  • 1Institut de Recerca Hospital Vall d'Hebron, Barcelona, Spain. smarsal@ir.vhebron.net

Pharmacogenomics
|April 27, 2010
PubMed
Summary

Pharmacogenomics aims to personalize rheumatoid arthritis treatment by identifying optimal therapies for individual patients. Future research will leverage advanced technologies and comprehensive data to improve treatment response for rheumatoid arthritis.

Area of Science:

  • Rheumatology and Immunology
  • Pharmacogenomics
  • Genetics

Background:

  • Rheumatoid arthritis (RA) is a complex and heterogeneous autoimmune disease.
  • Biological therapies have revolutionized RA treatment over the last decade.
  • A significant number of patients exhibit inadequate response to current biologic therapies.

Purpose of the Study:

  • To highlight the role of pharmacogenomics in optimizing rheumatoid arthritis treatment.
  • To emphasize the need for personalized therapeutic strategies in RA management.
  • To outline future directions for pharmacogenomic research in RA.

Main Methods:

  • Review of current literature on biological therapies and pharmacogenomics in RA.
  • Discussion of technological advancements and data requirements for personalized medicine.

Related Experiment Videos

Last Updated: Jun 13, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

  • Exploration of challenges and opportunities in implementing pharmacogenomic approaches.

    • Main Results:

    • Biological therapies have shown promise but lack universal efficacy in RA.
    • Patient heterogeneity significantly impacts treatment response.
    • Pharmacogenomics offers a pathway to predict and personalize RA therapy.

    Conclusions:

    • Personalized medicine is crucial for improving RA patient outcomes.
    • Advanced technologies and robust datasets are essential for pharmacogenomic advancements in RA.
    • Future pharmacogenomic studies will enable tailored treatment selection for individual RA patients.